KPTI | Karyopharm Therapeutics Inc. |
Pharmaceutical Preparations |
Book value per $ invested | $ -2.33 |
Leverage | 184.26% |
Market Cap | $ 68.5m |
PE | 0.00 |
Dividend Yield | 0.00% |
Profit | $ -86.1m |
Margin | -52.95% |
Karyopharm Therapeutics Inc., a pharmaceutical company, is dedicated to the discovery, development and commercialization of various drugs directed against nuclear export and related targets for the treatment of cancer and other diseases. The company is headquartered in Newton, Massachusetts.